SCHEMBL3515033

SCHEMBL3515033

O=C(O)c1c(O)c2cccnc2[nH]c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.54
PARP1 P09874 1/20 0.54
GRIN2D O15399 1/20 0.50
GRIN3B O60391 1/20 0.50
GRIN1 Q05586 1/20 0.50
GRIN2A Q12879 1/20 0.50
GRIN2B Q13224 1/20 0.50
GRIN2C Q14957 1/20 0.50
GRIN3A Q8TCU5 1/20 0.50
FGFR1 P11362 1/20 0.50
FLT1 P17948 1/20 0.50
KDM4E B2RXH2 3/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
DAO P14920 1/20 0.46
PADI4 Q9UM07 1/20 0.46
FEN1 P39748 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
LOXL3 P58215 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8852978 0.86 AURKA (0.53) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL4518985 0.86 AURKA (0.53) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL11157630 0.83 AURKA (0.53) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL4074442 0.83 AURKA (0.53) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL27651961 0.83 AURKA (0.53) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL822253 0.82 FTO (0.50) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL1063233 0.79 KDM5A (0.62) KDM4EMAPTMEN1KMT2AKDM5A
SCHEMBL16497485 0.79 AURKA (0.46) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL13598062 0.78 MEN1 (0.59) AURKAPARP1GRIN2DGRIN3BGRIN1
SCHEMBL11407079 0.77 AURKA (0.47) AURKAPARP1GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102015705-B Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2013-11-13 CN disclosed
CN-102015705-A Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-04-13 CN disclosed
US-20100056563-A1 NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS MERCK SHARP & DOHME CORP. 2010-03-04 US disclosed
US-4128649-A ANTIALLERGEN SANDOZ, INC. (US) 1978-12-05 US disclosed
US-4128649-A ANTIALLERGEN SANDOZ, INC. (US) 1978-12-05 US disclosed
US-4128649-A ANTIALLERGEN SANDOZ, INC. (US) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056563-A1 NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS HIF1AN, HIF1A, EGLN2 AURKA 2388/4885PARP1 585/4885GRIN2D 4799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.